MOLNUPIRAVIR — 200 mg capsules (LAGEVRIO®)

Oral antiviral • SARS-CoV-2 (COVID-19) • early outpatient treatment (selected adults) • authorization varies by country

Educational content only. Molnupiravir is an oral antiviral for COVID-19 with strict eligibility criteria and country-specific regulatory status.
Always follow local approved labeling and clinician guidance.

🔎 Quick Links

📦 Snapshot
🧠 Overview
🧾 Regulatory Status
⚠️ Safety
❓ FAQ
📚 References

📦 Product Snapshot

Active substanceMolnupiravir

Common brandLAGEVRIO®

Dosage formHard capsules, 200 mg

Typical adult regimen800 mg twice daily for 5 days (4 capsules per dose) — per some authorized labeling

Use is typically limited to adults with mild-to-moderate COVID-19 who are at risk of progression to severe disease,
and when preferred authorized/approved alternatives are not accessible or clinically appropriate (jurisdiction-dependent).

Drug classOral antiviral (nucleoside analogue prodrug)

How it works (plain language)Introduces errors during viral RNA replication (“error catastrophe”), reducing viable virus

When it works bestEarly in disease (first days after symptom onset), before severe inflammatory phase

Not intended for prophylaxis and not a substitute for vaccination. Not authorized for use in patients <18 years.

Request verified information

Use our inquiry form to request official leaflet links, verify standard pack details, and ask general authenticity/packaging questions.
We do not provide medical advice.International visitors: informational support and inquiries are available to users in the United States, United Kingdom, and Australia.

✉️ Request Information

Early treatment window • pregnancy precautions • eligibility rules vary

🧠 Overview

Molnupiravir is an oral antiviral developed for early outpatient treatment of COVID-19 in selected adult patients.
It is a prodrug that is converted to a ribonucleoside analogue; when incorporated into viral RNA, it increases the
mutation rate during replication, reducing production of viable virus.

Clinical positioning (practical): In multiple contemporary guidelines, molnupiravir is generally considered an
alternative option when preferred therapies (for example, nirmatrelvir/ritonavir or IV remdesivir) are unavailable,
unsuitable, or contraindicated for an individual patient. Recommendations and eligibility can change with variants,
population immunity, and local access pathways.

Time window: Treatment is typically started as soon as possible after diagnosis and within a short window
from symptom onset (commonly ~5 days, depending on jurisdiction/label).

🧾 Regulatory Status (High-level)

United States: LAGEVRIO (molnupiravir) has been available under FDA Emergency Use Authorization (EUA)
for certain adults with mild-to-moderate COVID-19 who are at high risk and when alternative options are not accessible/appropriate (see FDA/official HCP sources).
European Union (EMA): EMA’s CHMP recommended refusal of marketing authorisation; the company withdrew the application before re-examination concluded.
This means there is no EU central marketing authorisation based on that procedure.
United Kingdom: MHRA issued a conditional marketing authorisation historically (check current NHS/MHRA pathways and local formularies for present-day access rules).

Regulatory status can change (authorisations, procurement, reimbursement, access pathways). Always validate with the most current local regulator or health system source.

⚠️ Safety, Side Effects & Monitoring

Commonly reported adverse reactions

Diarrhea
Nausea
Dizziness
Headache

Exact frequencies vary by trial/population and over time; always use the local product information for your market.

Key precautions (high-impact)

• Pregnancy: avoid use in pregnancy; follow contraception guidance during treatment and for a period after the last dose (per local labeling).
• Age: not authorized for patients <18 years (potential effects on bone/cartilage growth).
• Early use: effectiveness depends on starting early after symptom onset.
• Not for prophylaxis: not intended for pre- or post-exposure prevention (jurisdiction-dependent restrictions).
• Drug interactions: compared with nirmatrelvir/ritonavir, major interaction burden is generally lower, but medication review is still required.

⛔ Contraindications / “do not use” signals (general)

Pregnancy (avoid; follow local label).
Age <18 years (not authorized).
Hypersensitivity to molnupiravir or formulation components.

Practical use reminders

Do not extend beyond the recommended course (commonly 5 days).
Missed dose: follow local label instructions; do not double-dose without guidance.
Red flags: worsening shortness of breath, persistent chest pain, confusion, cyanosis — seek urgent medical care (COVID can deteriorate regardless of antiviral use).

❓ FAQ

FAQ #1: Who is molnupiravir usually intended for?

In jurisdictions where it is authorized, molnupiravir is generally used for adults with mild-to-moderate COVID-19 who are
at risk of progression to severe disease, particularly when preferred antivirals are not suitable or available.

FAQ #2: Why is timing so important?

Antivirals work best when viral replication is highest—early in the course of illness. Most labels/guidelines specify
starting treatment as soon as possible and within a short window after symptom onset.

FAQ #3: Can it be used in pregnancy?

Typically avoid in pregnancy. If pregnancy is possible, follow contraception instructions in the local product information.
If pregnancy occurs or is suspected, contact a clinician immediately.

FAQ #4: Is it authorized in the EU?

EMA’s CHMP recommended refusal of EU marketing authorisation, and the company withdrew the application before the re-examination concluded.
Always check your specific country’s regulator for local/exceptional pathways.

FAQ #5: What are the official sources I should trust?

Use regulator/health-system sources (FDA, MHRA, WHO, CDC/IDSA, NICE/NCBI) and the manufacturer’s official HCP pages.
Avoid social-media dosing claims or off-label self-treatment.